Abstract
Transient tachypnea of the newborn results from delayed clearance of lung fluid and is a common cause of admission of full term and late preterm infants to neonatal intensive care units. The condition is particularly common after elective cesarean section. Conventional treatment involves supplemental oxygen, withholding enteral feeds and administration of intravenous fluids and antibiotics. Rarely, infants require CPAP and mechanical ventilation. Occasionally some babies develop severe hypoxemia and may require high concentrations of oxygen. The most effective strategy for accelerating reabsorbtion of fetal lung fluid is exogenous glucocorticoids. Potential therapies for TTN must be based on an understanding of the physiology of normal fetal lung fluid clearence at bith. Furosemide, racemic epinephrine and inhaled β-agonists have been studied for possible benefit in TTN. The routine administration of these drugs can not be recommended unless additional data become available.
Keywords: Transient tachypnea, alveolar fluid, furosemide, racemic epinephrine, salbutamol, newborn, lung fluid, preterm infants, intravenous fluids, hypoxemia
Current Pharmaceutical Design
Title:Transient Tachypnea of the Newborn: The Treatment Strategies
Volume: 18 Issue: 21
Author(s): Murat Yurdakok and Eren Ozek
Affiliation:
Keywords: Transient tachypnea, alveolar fluid, furosemide, racemic epinephrine, salbutamol, newborn, lung fluid, preterm infants, intravenous fluids, hypoxemia
Abstract: Transient tachypnea of the newborn results from delayed clearance of lung fluid and is a common cause of admission of full term and late preterm infants to neonatal intensive care units. The condition is particularly common after elective cesarean section. Conventional treatment involves supplemental oxygen, withholding enteral feeds and administration of intravenous fluids and antibiotics. Rarely, infants require CPAP and mechanical ventilation. Occasionally some babies develop severe hypoxemia and may require high concentrations of oxygen. The most effective strategy for accelerating reabsorbtion of fetal lung fluid is exogenous glucocorticoids. Potential therapies for TTN must be based on an understanding of the physiology of normal fetal lung fluid clearence at bith. Furosemide, racemic epinephrine and inhaled β-agonists have been studied for possible benefit in TTN. The routine administration of these drugs can not be recommended unless additional data become available.
Export Options
About this article
Cite this article as:
Yurdakok Murat and Ozek Eren, Transient Tachypnea of the Newborn: The Treatment Strategies, Current Pharmaceutical Design 2012; 18 (21) . https://dx.doi.org/10.2174/1381612811209023046
DOI https://dx.doi.org/10.2174/1381612811209023046 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Potential and Mechanisms of Action of Mesenchymal Stromal Cells for Acute Respiratory Distress Syndrome
Current Stem Cell Research & Therapy The Chick Embryo Chorioallantoic Membrane as a Model for in vivo Research on Anti-Angiogenesis
Current Pharmaceutical Biotechnology Ageing as a Trait de Union Between Diabetes and Dementia for Frailty
CNS & Neurological Disorders - Drug Targets Systemic DNA Damage Response and Metabolic Syndrome as a Premalignant State
Current Molecular Medicine Efficacy and Cardiovascular Safety of Alpha Glucosidase Inhibitors
Current Drug Safety Beneficial Effects of the Mediterranean Diet on Metabolic Syndrome
Current Pharmaceutical Design Diabetic Cognitive Dysfunction: From Bench to Clinic
Current Medicinal Chemistry Erectile Dysfunction and Coronary Artery Disease in Patients with Diabetes
Current Diabetes Reviews Neuroprotective Methodologies of Co-Enzyme Q10 Mediated Brain Hemorrhagic Treatment: Clinical and Pre-Clinical Findings
CNS & Neurological Disorders - Drug Targets Endothelium: A Target for Harmful Actions of Metals
Current Hypertension Reviews Association of Risk Factors, Antimicrobial Resistance Trends and Occurrence of blaTEM, bla SHV and blaCTX M in Escherichia coli Causing Bacteremia
Infectious Disorders - Drug Targets Perivascular Adipose Tissue, Inflammation and Vascular Dysfunction in Obesity
Current Vascular Pharmacology Investigation of the Metal Bonding Properties of Some ARA-II Compounds Using Spectrofluorimetric Method
Current Drug Therapy Editorial
Current Medical Imaging Oxidative Stress and Cardiovascular Aging: Interaction Between NRF-2 and ADMA
Current Cardiology Reviews Treatment of Hypertension Induced Albuminuria
Current Pharmaceutical Design Pharmacologic Treatment for Prehypertension: To Treat or Not to Treat?
Recent Patents on Cardiovascular Drug Discovery Relationship between Proinflammatory Cytokines/Chemokines and Adipokines in Serum of Young Adults with Obesity
Endocrine, Metabolic & Immune Disorders - Drug Targets Traditional Chinese Medicine in Treatment of Metabolic Syndrome
Endocrine, Metabolic & Immune Disorders - Drug Targets The Concept of Titration can be Transposed to Fluid Management. But does is Change the Volumes? Randomised Trial on Pleth Variability Index During Fast-Track Colonic Surgery
Current Clinical Pharmacology